Supernus Pharmaceuticals (SUPN) Cost of Revenue: 2013-2025
Historic Cost of Revenue for Supernus Pharmaceuticals (SUPN) over the last 12 years, with Sep 2025 value amounting to $19.0 million.
- Supernus Pharmaceuticals' Cost of Revenue rose 7.86% to $19.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $77.7 million, marking a year-over-year increase of 8.70%. This contributed to the annual value of $77.9 million for FY2024, which is 7.01% down from last year.
- Per Supernus Pharmaceuticals' latest filing, its Cost of Revenue stood at $19.0 million for Q3 2025, which was up 12.71% from $16.8 million recorded in Q2 2025.
- In the past 5 years, Supernus Pharmaceuticals' Cost of Revenue registered a high of $26.1 million during Q4 2024, and its lowest value of $15.0 million during Q1 2021.
- Moreover, its 3-year median value for Cost of Revenue was $19.0 million (2025), whereas its average is $19.4 million.
- In the last 5 years, Supernus Pharmaceuticals' Cost of Revenue soared by 260.16% in 2021 and then crashed by 30.48% in 2024.
- Over the past 5 years, Supernus Pharmaceuticals' Cost of Revenue (Quarterly) stood at $17.0 million in 2021, then skyrocketed by 35.07% to $23.0 million in 2022, then fell by 14.49% to $19.6 million in 2023, then skyrocketed by 32.97% to $26.1 million in 2024, then grew by 7.86% to $19.0 million in 2025.
- Its Cost of Revenue was $19.0 million in Q3 2025, compared to $16.8 million in Q2 2025 and $15.8 million in Q1 2025.